In a landmark decision, the European Commission has approved ICOTYDE™ (icotrokinra), the first oral peptide designed to block the interleukin‑23 (IL‑23) receptor. Developed by Johnson & Johnson, this once‑daily pill ushers in a new era for systemic treatment of moderate‑to‑severe plaque psoriasis, offering patients both convenience and a favorable safety profile.
A First in Psoriasis Treatment
Plaque psoriasis affects an estimated 6.4 million people in Europe, with many patients cycling through topical therapies that fail to deliver lasting relief. Until now, systemic treatments have largely relied on biologics administered via injection. ICOTYDE™ changes that paradigm by delivering targeted IL‑23 inhibition in an oral peptide format.
Clinical data from the ICONIC Phase 3 program, which enrolled more than 2,500 patients, showed that approximately 70% of participants achieved clear or almost clear skin (IGA 0/1) and 55% reached PASI 90 at Week 16. Safety outcomes were comparable to placebo, with no new signals observed through Week 52. These results establish icotrokinra as a credible alternative to injectable biologics, combining efficacy with ease of use.
Johnson & Johnson’s Peptide Expansion
The approval of ICOTYDE™ reflects Johnson & Johnson’s broader strategy of expanding into peptide therapeutics. The company has steadily invested in peptide science through collaborations with Protagonist Therapeutics and internal development programs. Icotrokinra itself was co‑discovered under a license agreement with Protagonist, and J&J retains exclusive rights to develop peptide‑based IL‑23 antagonists across multiple indications.
Beyond psoriasis, icotrokinra is being studied in psoriatic arthritis, ulcerative colitis, and Crohn’s disease, underscoring J&J’s commitment to peptides as versatile tools in immunology. This expansion positions the company as one of the few global pharmaceutical leaders actively building a pipeline of peptide drugs across autoimmune and inflammatory conditions.
For patients, the shift from injections to oral dosing is more than a matter of convenience. Daily pills reduce barriers to adherence, eliminate injection‑site reactions, and align with patient preferences for less invasive therapies. As Professor Lluís Puig of Universitat Autònoma de Barcelona noted, “The approval of icotrokinra marks an important evolution in plaque psoriasis treatment. As the first targeted oral peptide designed to precisely block the IL‑23 receptor, it combines high levels of skin clearance, a favorable safety profile, and the convenience of once‑daily oral administration.”
A Defining Milestone
Johnson & Johnson’s Therapeutic Area Head for Immunology, Mark Graham, described the approval as “a defining milestone for eligible people living with moderate‑to‑severe plaque psoriasis.” The company is now working with European stakeholders to ensure patient access, aligning with International Psoriasis Council guidance that systemic therapy should follow if topical treatments fail after two cycles.
Looking Ahead
The European Commission’s approval of ICOTYDE™ represents the arrival of peptides as mainstream systemic therapies. With J&J expanding its peptide portfolio and icotrokinra advancing into multiple autoimmune indications, oral peptides are poised to reshape how chronic inflammatory diseases are treated.